Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is developing MIV-818, a pro-drug designed to selectively treat liver cancer cells and to minimize side effects. It has the potential to become the first liver-targeted, orally administered drug for patients with HCC. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list.
View Top Employees from Medivir ABWebsite | http://www.medivir.com |
Revenue | $76 million |
Employees | 46 (44 on RocketReach) |
Founded | 1988 |
Address | 7 Lunastigen Huddinge, Stockholm 141 22, SE |
Phone | (468) 407-6430 |
Technologies |
HTML,
Twitter,
Google Analytics
+18 more
(view full list)
|
Industry | Pharmaceutical Manufacturing, Manufacturing General, Drug Discovery, Pharmaceuticals, Research Development, Manufacturing |
Web Rank | 21 Million |
Keywords | Medivir |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies |
Looking for a particular Medivir AB employee's phone or email?
The Medivir AB annual revenue was $76 million in 2024.
Fredrik Oberg is the Chief Scientific Officer of Medivir AB.
44 people are employed at Medivir AB.
The NAICS codes for Medivir AB are [3254, 325, 32541, 32].
The SIC codes for Medivir AB are [28, 283].